THANK YOU HAVE VISITED THIS WEB
Showing posts with label cancer drug development. Show all posts
Showing posts with label cancer drug development. Show all posts

Pathology and therapeutics for Pharmacist

C L I N I C A L P H A R M A C Y has  been    defined   in  many different ways, according to the interests and outlook of the practitioner. We take a very broad definition, encompassing all aspects of the use of medicines in patients and of responding  patients’ concerns about their health. It is thus an    essential component of the practice of virtually all pharmacists, whether working in the comunnity, in hospital or in industry, and must be based on a sound knowledge of the mechanisms of disease and the principles of drug selection. It has been  a  principle  of  our  teaching  that  clinical pharmacy practice requires an understanding of the medical process and of the nature of serious diseases and their treatment. This must underlieany involvement of pharmacists in contributing to the management of patients, or in the diagnosis and management of minor illness. Since pharmacists have to work with clinicians, and there are  well   established   intellectual   disciplines   in medicine for diagnosis and management, aspiring clinical pharmacists need to understand the way in which doctors approach the diagnosis of disease and the treatment of patients







This ebook can be download at:

Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical response

 

Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response provides the most comprehensive body of knowledge available on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients. As a consequence of the intrinsic chromosomal and genetic instability of the tumor genome, it is generally believed that tailoring of chemotherapy in cancer patients might be achieved by molecular analysis of patient tumor DNA. In addition, to reduce the toxicity risk of patients, the tumor DNA information should be integrated with the available data on polymorphic drug-metabolizing enzyme and transporter genes mediating the exposure of patients to active drugs and/or their active metabolites. The chapters of this book clearly show how DNA information from both the host (germline) and the tumor should be taken into account for rational selection of drug therapies in cancer patients, an aspect that received little attention, despite its importance.

This ebook can be download at:
Please Download
Related Posts Plugin for WordPress, Blogger...
THANK YOU HAVE VISITED THIS WEB